Phibro Animal Health Corporation (PAHC) Earnings
Phibro Animal Health Corporation is expected to report next earnings on November 4, 2026 (in NaN days), with a consensus EPS estimate of $0.78. PAHC has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise +18.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 27, 2026 | $0.72 | $0.85 | +18.7% | $397M | +2.8% |
| May 7, 2026 | $0.72 | $0.76 | +5.6% | $384M | +4.5% |
| Feb 4, 2026 | $0.69 | $0.87 | +26.1% | $374M | +2.4% |
| Nov 5, 2025 | $0.59 | $0.73 | +23.7% | $364M | +5.3% |
| Aug 27, 2025 | $0.52 | $0.57 | +9.6% | $379M | +4.5% |
| May 7, 2025 | $0.52 | $0.63 | +21.2% | $348M | -4.0% |
| Feb 5, 2025 | $0.40 | $0.54 | +35.0% | $309M | -10.9% |
| Nov 7, 2024 | $0.25 | $0.35 | +40.0% | $260M | +6.6% |
| Aug 28, 2024 | $0.34 | $0.41 | +20.6% | $273M | +3.8% |
| Feb 7, 2024 | $0.27 | $0.33 | +22.2% | $250M | -0.5% |
| Aug 30, 2023 | $0.40 | $0.38 | -4.8% | $255M | +6.2% |
| May 3, 2023 | $0.34 | $0.29 | -14.7% | $246M | -5.1% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2026 · August 27, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- **Strategic Transformation**: The 'Fibro Forward' three-year transformation program has formally concluded, embedding stronger execution and accountability into the organization. It is expected to contribute approximately $50 million in cumulative EBITDA against the fiscal 2024 baseline. - **Acquisition Integration**: The integration of the MFA portfolio is progressing well, providing strategic benefits across the entire product line. Management no longer plans to report the acquired portfolio separately as it is fully integrated. - **Manufacturing Rationalization**: Fibro announced the closure of its Chicago Heights manufacturing facility to align the footprint with future needs. This decision aims to support long-term returns and operational efficiency, with ongoing costs managed responsibly. - **Regulatory Uncertainty**: There is significant uncertainty regarding the regulatory status of virginiamycin in Brazil. Management assumes minimal sales contribution from this region in their planning, viewing any favorable outcome as upside rather than a requirement to meet guidance. - **Operational Efficiency**: Gross margins are expected to remain flat, offsetting negative impacts from regulatory changes with efficiencies from Fibro Forward and cost savings from the Chicago Heights closure.
Guidance
- **Net Sales**: Expected between $1.55 billion and $1.60 billion for fiscal year 2027, representing 2-5% growth with a midpoint of approximately 4%. - **Adjusted EBITDA**: Projected at $258 million to $268 million, reflecting 1-5% growth with a midpoint of approximately 3%. - **Adjusted EPS**: Anticipated between $3.41 and $3.59 per share. - **Tax Rate**: Adjusted effective income tax rate expected to be approximately 20%. - **Seasonality Note**: Q1 fiscal 2027 is expected to have negative EBIT growth due to a higher SG&A base carried forward from FY26 infrastructure build-out; positive growth is expected for the remainder of the year.
Segment performance
The company reported consolidated net sales of $1.52 billion for the full year ended June 30, 2026, a 17% increase year-over-year. The Animal Health segment was the primary growth driver, posting $1.16 billion in net sales (up 21%) with adjusted EBITDA of $303.6 million (up 37%). This growth was fueled by the integration of the new MFA business ($354.3 million in sales, up 70%) and strong legacy performance in antimicrobials, nutritional specialties, and vaccines. Mineral Nutrition generated $282.3 million in net sales (up 11%) but saw modest EBITDA growth of 4% due to higher input costs. Performance Products declined, with net sales of $73.5 million (down 8%) and adjusted EBITDA dropping to $8.1 million.
Risks & headwinds
- **Regulatory Delays**: The potential loss or delay of therapeutic claims for virginiamycin in Brazil poses a risk to revenue and EBITDA, particularly given the product's high margin profile. - **Cost Inflation**: Rising commodity prices for minerals (zinc, copper) have pressured margins in the Mineral Nutrition segment, limiting EBITDA growth despite revenue increases. - **Integration Costs**: Higher SG&A expenses related to employee costs and strategic investments associated with integrating the new MFA business. - **Inventory Volatility**: Significant inventory builds in FY26 impacted free cash flow; while stabilized, further transitions (e.g., Chicago Heights) require careful working capital management.
Analyst Q&A
Q: Erin Wright asked about the decline in the new MFA portfolio sales in Q4 and underlying demand trends by species.
A: Management clarified that the Q4 decline was due to a difficult prior-year comparator, not weak underlying trends, and expects the portfolio to outpace overall revenue growth in FY27 driven by North American momentum and international growth. Larry Miller added that demand remains strong across meat and dairy sectors as animal values hit record highs, motivating investment in health products. The acquired anticoccidial portfolio complements legacy offerings, allowing for strategic rotation programs in poultry and repositioned cattle solutions.
Q: Ekaterina Kiskova requested details on margin assumptions, business development appetite, and updates on the Brazilian regulatory review for virginiamycin.
A: Glenn David stated gross margins are expected to remain flat, offsetting regulatory headwinds with efficiencies and Chicago Heights closure benefits, while SG&A will grow slightly faster than revenue. Donny Bendheim noted active BD focus on vaccines, nutrition, companion animals, and climate, prioritizing internal opportunities first. Larry Miller expressed optimism for receiving therapeutic approval in Brazil within the 180-day transition period, noting competitive disadvantages if approval is delayed compared to other markets.
Q: Daniel Grossleit focused on FY27 free cash flow, working capital dynamics, and one-time costs associated with the Chicago Heights closure.
A: Glenn David explained that while FY26 FCF was limited by an $86M inventory build from acquisitions, FY27 inventory growth is expected to be limited to $25-30M for the Chicago Heights transition. CapEx will rise to fund vaccine capacity in Ireland and Israel. One-time cash costs for the closure are estimated at ~$10M, with additional CapEx of ~$10M. Ongoing annual EBITDA benefits of $15-20M are expected to materialize in FY28 and beyond.
Q: Michael Riskin inquired about mineral nutrition visibility, the post-Fibro Forward strategy, and companion animal product performance.
A: Glenn David highlighted that while mineral nutrition revenue grew 11%, EBITDA growth was only 4% due to pass-through commodity cost inflation, expecting slower revenue but stronger EBITDA growth in FY27. Donny Bendheim confirmed no 'Fibro Forward 2.0' but emphasized continuous strategic implementation. Regarding companion animals, Regensa is growing with expanded distribution, while Restoris is in early stages with reorders increasing but below initial expectations; management has tempered FY27 guidance for this segment.